Amylyx Pharma Q2 EPS $0.31 Beats $0.10 Estimate, Sales $98.20M Beat $92.14M Estimate
Portfolio Pulse from Benzinga Newsdesk
Amylyx Pharma (NASDAQ:AMLX) reported Q2 earnings of $0.31 per share, beating the analyst consensus estimate of $0.10 by 210%. This is a 133.33% increase over losses of $(0.93) per share from the same period last year. The company also reported quarterly sales of $98.20 million, beating the analyst consensus estimate of $92.14 million by 6.58%.
August 10, 2023 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amylyx Pharma's Q2 earnings and sales exceeded analyst estimates, indicating a strong financial performance.
Amylyx Pharma reported a significant increase in earnings per share and sales, both beating analyst estimates. This indicates a strong financial performance, which is likely to positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100